MARKET WIREYahoo • 6d ago
Why This Hair Restoration Biotech's Shares Are SoaringVeradermics' shares are up nearly 270% since its IPO earlier this year.
Why MANE Stock Traded Steady Today — RQD Quant Desk Flash
$143.85 +0.01% NYSE • Public Delayed / 60s Snapshot
Veradermics Incorporated (MANE) carries a Roarable Rating of D+ (Sell) with 58/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh money.
ROARABLE D+ • SELL / AVOID
Cap $6.01B
INTERACTIVE SCENARIO DECK:
RQD QUANT TACHOMETERSELL / AVOID • D+
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
5-PILLAR SNOWFLAKE RADARRw D · Rk B
Each axis scored 0–20
12M PRICE TARGET CONE+0% Base Target
WHALE OPTIONS TUG-OF-WAR:58% Call Buyers ($2.6M)
42% PutsMax Pain: $141.00
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MANE Stock Traded Steady Today — RQD Quant Desk Flash
Veradermics Incorporated (MANE) advanced +0.01% to $143.85 as options desks priced 58% call premium vs. 42% put protection around the $141 max-pain magnet. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 98% of its 52-week range ($32 – $146.58) with RSI-14 at 62.8 (BULLISH MOMENTUM).
- ▸Whale Options Positioning: $2.6M in bullish call flow vs. $1.9M in put flow (Put/Call 0.72x, implied earnings swing ±7.1%).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 0% gross margin and $0 annual free cash flow.
Live MANE Headlines & Catalysts
CATALYSTBenzinga • 9d ago
B. Riley Securities Maintains Buy on Veradermics, Raises Price Target to $204B. Riley Securities analyst Mayank Mamtani maintains Veradermics (NYSE:MANE) with a Buy and raises the price target from $170 to $204.
RISK WATCHYahoo • 9d ago
Could This Pill Be a Game Changer for Hair Loss? Veradermics Reports Major BreakthroughOn Monday, Veradermics Incorporated announced positive topline results from Part A of its registration-directed Phase 3 trial evaluating an experimental oral hair loss medication. Following the announcement, the stock ju
RISK WATCHYahoo • 12d ago
Veradermics’ stock up on male hair loss trial successThe company said that its drug could be the first approved by the FDA for this patient population in almost three decades.
RISK WATCHYahoo • 12d ago
Veradermics Soars 10% as Phase 3 Data Show Oral Hair-Loss Pill Could “Transform” TreatmentKey TakeawaysVeradermics shares are up 10% today after its oral hair-loss pill, VDPHL01, met every primary and secondary goal in its second Phase 3 trial in men. Two trials with more than 1,000 men now show nearly the sa
CATALYSTYahoo • 12d ago
Veradermics Phase III Hair Loss Trial Meets All Endpoints, Posts Strong Growth ResultsVeradermics (NYSE:MANE) reported positive top-line results from Part A of Study 304, its second Phase III trial of VDPHL01, an extended-release oral minoxidil tablet being developed for men with mild to moderate pattern
RISK WATCHSeekingAlpha • 12d ago
Veradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss TranscriptVeradermics, Incorporated (MANE) Discusses Positive Top Line Results From Phase III Study 304 of VDPHL01 in Male Pattern Hair Loss October 19, 2026 8:00 AM...
CATALYSTYahoo • 12d ago
Veradermics stock surges as hair loss drug meets Phase 3 goalsInvesting.com -- Veradermics Inc (NYSE:MANE) shares rose 6.7% in premarket trading Monday after the company announced its oral hair loss drug VDPHL01 met all primary and secondary endpoints in a Phase 3 clinical trial.
MARKET WIREYahoo • 12d ago
Roche inks $15B ADC pact with Hansoh; Veradermics scores in another baldness studyRoche is paying Hansoh $400 million up front in a broad deal involving several ADCs. Elsewhere, another top investor formed a China-focused fund and Ultragenyx sold a second review voucher.
MARKET WIREYahoo • 12d ago
Veradermics’ Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 3 ‘304’ Clinical Trial in Male Pattern Hair LossNEW HAVEN, Conn., October 19, 2026--Veradermics, Incorporated (NYSE: MANE), a dermatologist-founded, late-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announc
🔴 SUNDAY NIGHT PREP • 7:00 PM ETHosted Live by Perry Belcher & Guest Forensic Quant Desk
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring MANE)
- ✓Live walkthrough of MANE's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
RQD INSIDER CLUB UPGRADE$49/YEAR
Want Plain-English AI Custom Indicators, Daily Pro Trader Video Clips & SMS Crash Alerts?
MANE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +41.10%▲ RESISTANCE BREAKOUT
2026-10-30O $141.8H $145.4L $138.3C $139.7VOL 464.8K
RES: $138.0SUP: $101.3SMA50: $114.6SMA200: $93.84
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MANE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
17.8%/yr Implied 5Y Growth
vs. +4.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MANE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MANE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MANE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
MANE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MANE stock moving today?
Why MANE Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-12% return on capital) under elevated 10-year interest-rate pressure.